[Treatment of cerebral malaria with a fansidar-hydergine combination].
D000293:Adolescent; D000328:Adult; D000962:Antimalarials / Q000627:therapeutic use*; D001927:Brain Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D003128:Coma / Q000209:etiology; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004877:Ergoloid Mesylates / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008288:Malaria / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D008297:Male; D009461:Neurologic Manifestations; D010963:Plasmodium falciparum / Q000302:isolation & purification; D011739:Pyrimethamine / Q000008:administration & dosage / Q000627:therapeutic use*; D013412:Sulfadimethoxine / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D000962:Antimalarials; D004338:Drug Combinations; D013412:Sulfadimethoxine; D004877:Ergoloid Mesylates; D011739:Pyrimethamine
Traitement du paludisme neurologique par l'association fansidar-hydergine.